Author

L Gellis

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5159671713

Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials

2026 · E S G Stroes, C M Ballantyne, et al. · European Heart Journal

Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trials

2026 · P Corral, J A Parham, et al. · European Heart Journal

Works count: 2

Citation count:

H-index:

I10-index: